Ketoconazole treatment of chronic mucocutaneous candidiasis

Publisher Website
Google Scholar
Abstract
Five patients received ketoconazole treatment of chronic mucocutaneous candidiasis. One also had disseminated histoplasmosis and cryptococcosis. Ketoconazole was well absorbed after an oral dose of 200 mg and produced detectable anti-fungal blood levels for > 8 h after each dose. Thrush cleared in < 2 wk in all patients. Cutaneous lesions cleared slowly during several months of treatment. A patient with polymycotic infection had a rapid clearing of candidiasis but her histoplasmosis did not respond to 3 wk of treatment. Adverse drug effects were minimal. Ketoconazole is a promising new agent for the treatment of chronic mucocutaneous candidiasis.